Author:
Ibishev Khalid Suleymanovich,Krahotkin Denis Valerievich,Mammadov Vahid Kamalovich,Singe Andrey Ivanovich
Abstract
Introduction: Chronic recurrent cystitis (CRC) for women is one of the most pressing and unresolved problems of modern urology. Purpose of the research: To study the effectiveness of Alloferon (Allokin-alpha) in the complex therapy of chronic reactive papillomavirus cystitis. Materials and methods: 46 patients with CRC PV-etiology were examined, which, depending on the therapy, were randomized into two groups. Patients of group I (n=22) received combination therapy supplemented with Alloferon, which was injected subcutaneously every 1 day, for a course of 6 injections. Group II (control) (n=24) - combination therapy without study drug. The effectiveness of treatment was assessed immediately after treatment, after 1, 3, 6 months, from the beginning of therapy. Results: When analyzing the results of treatment, a significant improvement in clinical indicators was noted in patients of group I who received complex therapy, which included Alloferon, after 1 month from the start of treatment, there was a significant decrease in pain symptoms and LUTS, an improvement in the quality of life of patients compared with group II. When evaluating the dynamics of laboratory data, in the general analysis of urine, a significant decrease in the level of leukocytes and erythrocytes in the general analysis of urine was noted. In addition, the analysis of the data of cytological examination of urine revealed a decrease in the specific sign of papillomavirus lesions of the bladder - coylocytosis: after 6 months. From the start of therapy, no coylocytes were detected in group I, while in group II, coylocytes in urine were detected in 8 (33.3%) patients. Conclusions: The use of Alloferon (Allokin-alpha) in the complex therapy of patients with CRC PV etiology improved clinical and laboratory parameters after 1 month. after starting therapy, while the undoubted advantage of the drug is a faster reduction in pain, which significantly increased the quality of life.
Reference15 articles.
1. Gadzhieva Z.K., Kazilov Yu.B. Features of the prevention of recurrent lower urinary tract infections. Urologiia. 2016;(3):65-76. Russian (Гаджиева З.К., Казилов Ю.Б. Особенности подхода к профилактике рецидивирующей инфекции нижних мочевыводящих путей. Урология. 2016;(3):65-76).
2. Kuz'min I.V., Slesarevskaya M.N., Al'-Shukri S.KH. D-mannose for the prevention and treatment of lower urinary tract infections: pathogenetic basis and clinical results. Urologiia. 2020;(4):131-138. Russian (Кузьмин И.В., Слесаревская М.Н., Аль-Шукри С.Х. D-манноза в профилактике и лечении инфекций нижних мочевыводящих путей: патогенетические основы и клинические результаты. Урология. 2020;(4):131-138).
3. Lee P.J., Kuo H.C. High incidence of lower urinary tract dysfunction in women with recurrent urinary tract infections. Low Urin Tract Symptoms. 2020;12(1):33-40.
4. Ibishev KH.S. A modern perspective on the treatment and prevention of recurrent lower urinary tract infections. Effektivnaya farmakoterapiya. 2015;(26):28-30. Russian (Ибишев Х.С. Современный взгляд на лечение и профилактику рецидивирующей инфекции нижних мочевых путей. Эффективная фармакотерапия. 2015;(26):28-30).
5. Kuz'menko A.V., Kuz'menko V.V, Gyaurgiyev T.A. Current trends in the treatment of chronic recurrent bacterial cystitis. Urologiia. 2020;(6): 52-57. Russian (Кузьменко А.В., Кузьменко В.В, Гяургиев Т.А. Современные тенденции в лечении хронического рецидивирующего бактериального цистита. Урология. 2020;(6):52-57).